Cite
Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer
MLA
Colby S. Shemesh, et al. “Population Pharmacokinetics, Exposure-Safety, and Immunogenicity of Atezolizumab in Pediatric and Young Adult Patients with Cancer.” Journal for ImmunoTherapy of Cancer, vol. 7, no. 1, Nov. 2019, pp. 1–13. EBSCOhost, https://doi.org/10.1186/s40425-019-0791-x.
APA
Colby S. Shemesh, Pascal Chanu, Kris Jamsen, Russ Wada, Gianluca Rossato, Francis Donaldson, Amit Garg, Helen Winter, Jane Ruppel, Xin Wang, Rene Bruno, Jin Jin, & Sandhya Girish. (2019). Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer. Journal for ImmunoTherapy of Cancer, 7(1), 1–13. https://doi.org/10.1186/s40425-019-0791-x
Chicago
Colby S. Shemesh, Pascal Chanu, Kris Jamsen, Russ Wada, Gianluca Rossato, Francis Donaldson, Amit Garg, et al. 2019. “Population Pharmacokinetics, Exposure-Safety, and Immunogenicity of Atezolizumab in Pediatric and Young Adult Patients with Cancer.” Journal for ImmunoTherapy of Cancer 7 (1): 1–13. doi:10.1186/s40425-019-0791-x.